Enhancing Language Function in Aphasia

Sponsor
University of Arizona (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05443633
Collaborator
(none)
30
1
2
75.5
0.4

Study Details

Study Description

Brief Summary

Aphasia is an acquired impairment of language, that commonly results from damage to language areas in the brain (typically the left side of the brain). This impairment is seen in many aspects of language, including understanding, speaking, reading and writing. It is estimated that about 2 million individuals are currently living with aphasia in the United States. Further, about 200,000 Americans acquire aphasia every year (National Aphasia Association, 2020). Aphasia poses significant impact on the affected individuals and their families. Behavioral treatments that target language deficits have been shown to enhance overall communication skills and life satisfaction among individuals with aphasia. Although there is evidence that suggests that treatment is efficacious for individuals with aphasia, the extent of improvement long-term coupled with the neural patterns among those individuals are largely unknown. The current study aims to investigate the efficacy of language-based treatment and its corresponding neural patterns.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: individualized speech-language training
  • Behavioral: standard language intervention
N/A

Detailed Description

The purpose of this study is to develop semantic-based treatment to address language deficits in individuals with acquired language disorders. We propose to develop an individually optimized semantic-based protocol for strategy implementation and word finding facilitation among individuals with language disorders.

Phase 1: Following screening, participants who fulfill the inclusion criteria and have consented to participate in the study will undergo baseline cognitive and language assessment, electroencephalography (EEG) recording and the magnetic resonance imaging (MRI) scan. Participants with language disorders will proceed to the following phases.

Phase 2: After baseline assessment, participants will undergo individualized language treatment in which they will learn semantically- or phonologically based strategies to facilitate word finding difficulties, sentence formulation, or challenges in their narration and discourse. The level at which the treatment will be administered will depend on the participants' level of performance determined by the results of the language and cognitive testing done at baseline. Treatment will be administered twice a week for 10 weeks.

Phase 3: Directly following treatment, patients will undergo cognitive and language assessment, EEG recording, and an MRI scan. This is done to test for short-term changes in behavioral abilities and neural patterns.

Phase 4: After 2 months after the treatment, participants will undergo cognitive and language assessment, EEG recording, and an MRI scan. This final phase of testing is done to test for long-term changes in behavioral abilities and neural responses.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Intervention Model Description:
individuals will be randomized to the active intervention or control group (standard care)individuals will be randomized to the active intervention or control group (standard care)
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description:
The subject codes will be used for blinding of the participants, care-providers, and assessors
Primary Purpose:
Treatment
Official Title:
Enhancing Language Function in Aphasia Using Behavioral Language Intervention
Anticipated Study Start Date :
Aug 30, 2022
Anticipated Primary Completion Date :
Jun 30, 2027
Anticipated Study Completion Date :
Dec 15, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active therapy group

Participants will undergo individualized language treatment in which they will learn semantically- or phonologically based strategies to facilitate word finding difficulties, sentence formulation difficulties, or challenges in their narration and discourse. The level at which the treatment will be administered will depend on the participants' level of performance determined by the results of the language and cognitive testing done at baseline. Treatment will be administered twice a week for 10 weeks.

Behavioral: individualized speech-language training
Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
Other Names:
  • active
  • Active Comparator: control group

    control group will undergo standard speech-language intervention

    Behavioral: standard language intervention
    Participants will undergo standard speech-language naming therapy
    Other Names:
  • control
  • Outcome Measures

    Primary Outcome Measures

    1. Mean change from baseline scores on the naming task [through study completion, an average of 1 year]

      Mean change from baseline scores on the Boston Naming Test: Min score = 0; Max = 60; higher scores indicate better outcome

    2. Mean change from baseline scores in aphasia severity [through study completion, an average of 1 year]

      Mean change from baseline scores on the Western Aphasia Battery: Min score = 0; Max = 100; higher scores indicate better outcome

    3. Mean change from baseline scores on the language probe task before and after each session [through study completion, an average of 1 year]

      change on on the probe task from before the session; Min =0; Max = 100%; higher scores indicate better outcome

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Present with speech-language impairment (aphasia) caused by stroke or dementia

    2. A medical diagnosis of primary progressive aphasia (PPA) by a neurologist or physician

    3. Are native speakers of English

    4. Present with no contraindications for MRI

    5. Have adequate (normal or corrected to normal) vision and hearing

    Exclusion Criteria:
    1. Individuals diagnosed with mood, anxiety, psychotic or substance abuse disorders.

    2. Individuals with highly magnetizable metallic implants, including certain dental work, may be excluded due to image quality in MRI.

    3. Individuals with other neurological disorders besides the ones of interest for the study (e.g., epilepsy, Multiple Sclerosis, Parkinson's Disease)

    4. Individuals with contraindications for MRI. This includes but is not limited to pacemakers, metallic cardiac pumps, valves, magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field.

    5. Individuals suffering from clinically significant claustrophobia

    6. Severe systemic disease (e.g., renal failure)

    7. Poor overall health

    8. Individuals who are pregnant

    9. Individuals with a history of epileptic activity in the past 12 months

    10. Individuals with a personal or family history of epilepsy or other seizure disorders will not be included in the study.

    11. Individuals who have had a brain surgery in the past

    12. Individuals with implanted metallic skull plates or intracranial implants

    13. Individuals with skin lesions or skull damage

    14. Individuals who have a history of excessive use of alcohol or drugs

    15. Individuals with premorbid psychiatric disease affecting communication

    16. Individuals with severe non-linguistic cognitive disturbances impeding language therapy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Arizona Tucson Arizona United States 85721-0071

    Sponsors and Collaborators

    • University of Arizona

    Investigators

    • Principal Investigator: Aneta Kielar, PhD, University of Arizona

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Arizona
    ClinicalTrials.gov Identifier:
    NCT05443633
    Other Study ID Numbers:
    • STUDY00001134
    First Posted:
    Jul 5, 2022
    Last Update Posted:
    Jul 8, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 8, 2022